Last reviewed · How we verify
Moraxella Catarrhalis Chronic Bronchitis
Approved treatments
- Avelox · Bayer AG
Fourth-generation fluoroquinolone with the broadest spectrum, covering gram-positive, gram-negative, anaerobic, and atypical organisms. - Ceclor
- Ciprofloxacine · Poitiers University Hospital
- Cefzil · Teva Pharmaceuticals USA
- Avelox · Novartis Pharmaceuticals
- Zymar · Allergan
- Cedax · Burke Therap
- Cefditoren Pivoxyl · Vansen Pharma
- Noroxin
- Floxin
- Cipro · Bayer AG
- CEFDITOREN
- Ofloxacine · Assistance Publique - Hôpitaux de Paris
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moraxella Catarrhalis Chronic Bronchitis patent landscape — cliff calendar, originator estates, attackable patents
- Moraxella Catarrhalis Chronic Bronchitis treatment landscape brief
- Moraxella Catarrhalis Chronic Bronchitis treatment updates RSS
Frequently asked questions about Moraxella Catarrhalis Chronic Bronchitis
What drugs treat Moraxella Catarrhalis Chronic Bronchitis?
Tracked treatments include Avelox, Ceclor, Ciprofloxacine, Cefzil, Zymar, Cedax, Cefditoren Pivoxyl, Noroxin.
What is the treatment for Moraxella Catarrhalis Chronic Bronchitis?
Standard treatment for Moraxella Catarrhalis Chronic Bronchitis includes Avelox, Ceclor, Ciprofloxacine, Cefzil, Zymar. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moraxella Catarrhalis Chronic Bronchitis patent cliff · Moraxella Catarrhalis Chronic Bronchitis CI report
- Treatment: Avelox · Bayer AG
- Treatment: Ceclor
- Treatment: Ciprofloxacine · Poitiers University Hospital
- Treatment: Cefzil · Teva Pharmaceuticals USA
- Treatment: Avelox · Novartis Pharmaceuticals
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing